<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16935</article-id><article-id pub-id-type="doi">10.25208/vdv16935</article-id><article-id pub-id-type="edn">rtwpxm</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The effectiveness of antifungal drugs in dermatomycosis: a systematic review with network analysis</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность противогрибковых препаратов при дерматомикозах: систематический обзор с сетевым анализом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9458-0872</contrib-id><contrib-id contrib-id-type="spin">2287-5062</contrib-id><name-alternatives><name xml:lang="en"><surname>Samtsov</surname><given-names>Alexey V.</given-names></name><name xml:lang="ru"><surname>Самцов</surname><given-names>Алексей Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>avsamtsov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0387-5481</contrib-id><contrib-id contrib-id-type="spin">4417-9117</contrib-id><name-alternatives><name xml:lang="en"><surname>Khairutdinov</surname><given-names>Vladislav</given-names></name><name xml:lang="ru"><surname>Хайрутдинов</surname><given-names>Владислав Ринатович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>haric03@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1375-056X</contrib-id><contrib-id contrib-id-type="spin">3393-3256</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbunov</surname><given-names>Yuri G.</given-names></name><name xml:lang="ru"><surname>Горбунов</surname><given-names>Юрий Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Can. Sci. (Med.), Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>urikgor@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.M. Kirov Military Medical Academy</institution></aff><aff><institution xml:lang="ru">Военно-медицинская академия им. С.М. Кирова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-01-19" publication-format="electronic"><day>19</day><month>01</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-02-06" publication-format="electronic"><day>06</day><month>02</month><year>2026</year></pub-date><volume>101</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2025-09-06"><day>06</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-12-10"><day>10</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Samtsov A.V., Khairutdinov V., Gorbunov Y.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Самцов А.В., Хайрутдинов В.Р., Горбунов Ю.Г.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Samtsov A.V., Khairutdinov V., Gorbunov Y.G.</copyright-holder><copyright-holder xml:lang="ru">Самцов А.В., Хайрутдинов В.Р., Горбунов Ю.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/16935">https://vestnikdv.ru/jour/article/view/16935</self-uri><abstract xml:lang="en"><p>Dermatomycosis has a significant impact on the quality of life of patients of any age in all socio-economic regions and requires therapy.</p> <p>Aim of the review — to compare the effectiveness of topical therapy of dermatomycosis with amorolfine, azole (clotrimazole, ketoconazole) and allylamine (terbinafine, naftifine) groups using a systematic review of randomized clinical trials and synthesis of its results based on a network meta-analysis.</p> <p>The review includes non-placebo-controlled randomized trials of the efficacy of amorolfine, clotrimazole, ketoconazole, terbinafine, and naftifine with a therapy duration of up to four weeks. The percentage of patients who achieved a mycological and clinical cure was chosen as the endpoint of effectiveness. The assessment of the effect size in the analysis is represented by the risk difference. The drugs in question are ranked based on surface under the cumulative ranking curve (SUCRA).</p> <p>The data from 7 studies involving about 769 patients with dermatomycosis were statistically analyzed. The results showed almost equivalent efficacy of amorolfine and terbinafine, superior to ketoconazole, and clotrimazole in cream formulations. Ranking the effectiveness of drugs using SUCRA revealed amorolfine as the most effective therapy among other drugs.</p> <p>The analysis of the study results included in the systematic review showed the advantage of amorolfine in the formulation of cream over terbinafine, ketoconazole, clotrimazole, naftifine.</p></abstract><trans-abstract xml:lang="ru"><p>Дерматомикозы оказывают значительное влияние на качество жизни пациентов любого возраста во всех социально-экономических регионах и нуждаются в проведении терапии.</p> <p>Цель обзора — сравнение эффективности топической терапии дерматомикозов аморолфином, препаратами классов азолов (клотримазолом, кетоконазолом) и аллиламинов (тербинафином, нафтифином) с помощью систематического обзора рандомизированных клинических исследований и синтеза его результатов на основе сетевого метаанализа.</p> <p>В обзор включены неплацебо-контролируемые рандомизированные исследования эффективности аморолфина, клотримазола, кетоконазола, тербинафина, нафтифина в лекарственной форме крема с длительностью терапии до 4 недель. Конечной точкой эффективности выбрана доля пациентов, достигших микологического и клинического выздоровления. Оценка терапевтического эффекта в анализе представлена разницей рисков. Рассматриваемые препараты ранжированы на основе значений площади под кумулятивной ранжирующей кривой (surface under the cumulative ranking curve, SUCRA).</p> <p>Статистическому анализу подверглись данные семи исследований с участием 769 пациентов с дерматомикозами. Анализ результатов показал практически эквивалентную эффективность аморолфина и тербинафина, превосходящую эффективность терапии кетоконазолом и клотримазолом. Ранжирование эффективности препаратов с помощью SUCRA выявил аморолфин как наиболее эффективную терапию среди остальных препаратов.</p> <p>Анализ результатов исследований, включенных в систематический обзор, показал преимущество аморолфина в форме крема над тербинафином, кетоконазолом, клотримазолом, нафтифином.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dermatomycoses</kwd><kwd>amorolfine</kwd><kwd>skin cream</kwd><kwd>network meta-analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дерматомикоз</kwd><kwd>аморолфин</kwd><kwd>крем</kwd><kwd>сетевой анализ</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The article was prepared with the support of the Glenmark company.</funding-statement><funding-statement xml:lang="ru">Статья подготовлена при поддержке компании «Гленмарк».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl_4):2–15. doi: 10.1111/j.1439-0507.2008.01606.x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Li D, Fan S, Zhao H, Song J, Guo L, Li W, et al. Worldwide trends and future projections of fungal skin disease burden: a comprehensive analysis from the Global Burden of Diseases study 2021. Front Public Health. 2025;13:1580221 doi: 10.3389/fpubh.2025.1580221</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Liu X, Zhang Y, Hong Y, Zhang H. Global burden of fungal skin diseases: An update from the Global Burden of Diseases Study 2019. Mycoses. 2024;67(7):e13770 doi: 10.1111/myc.13770</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;3:CD001434. doi: 10.1002/14651858.CD001434.pub2</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153(5):406–412. doi: 10.1001/jamadermatol.2016.5538</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс; 2016. 768 с. [Federal’nye klinicheskie rekomendacii. Dermatovenerologija 2015: Bolezni kozhi. Infekcii, peredavaemye polovym putem. (Federal clinical guidelines. Dermatovenerology 2015: Skin diseases. Sexually transmitted infections.) 5th ed., revised and expanded. Moscow: Delovoj jekspress; 2016. 768 p. (In Russ.)]</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Mochizuki T, Tsuboi R, Iozumi K, Ishizaki S, Ushigami T, Ogawa Y, et al. Guidelines for the management of dermatomycosis (2019). J Dermatol. 2020;47(12):1343–1373. doi: 10.1111/1346-8138.15618</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Егорова Е.А., Шейхмамбетова Л.Н., Бекирова Э.Ю. Маркетинговый анализ ассортимента противогрибковых препаратов для местного применения на фармацевтическом рынке Российской Федерации. Современная организация лекарственного обеспечения. 2021;1:7–13. [Egorova EA, Sheikhmambetova LN, Bekirova EYu. Market analysis of the range of antifungal drugs for local use on the pharmaceutical market of the Russian Federation. Sovremennaja Organizacija Lekarstvennogo Obespechenija. 2021;1:7–13. (In Russ.)] doi: 10.30809/solo.1.2021.1</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Цибизова А.А., Макалатия М.К. Маркетинговые исследования фармацевтического рынка противогрибковых препаратов. Прикаспийский вестник медицины и фармации. 2023;4(2):61–66. [Tsibizova AA, Makalatiya MK. Marketing research of pharmaceutical market of antifungal drugs. Caspian Journal of Medicine and Pharmacy. 2023;4(2):61–66. (In Russ.)] doi: 10.29039/2712-8164-2023-2-61-66</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Тамразова О.Б. Наружные антимикотики в терапии поверхностных микозов кожи. Клинический разбор в общей медицине. 2024;5(6):82–88. [Tamrazova OB. Topical antifungals in treatment of superficial cutaneous mycoses. Clinical Analysis in General Medicine. 2024;5(6):82–88. (In Russ.)] doi: 10.47407/kr2024.5.6.00439</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981;76(6):438–441. doi: 10.1111/1523-1747.ep12521036</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol. 1990;23(4Pt2):782–785. doi: 10.1016/0190-9622(90)70288-s</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NL, Correr CJ. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341–349. doi: 10.1001/jamadermatol.2013.1721</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49(1):103–120. doi: 10.2165/00003495-199549010-00008</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Общая характеристика лекарственного препарата ОФЛОМИЛ ДЕРМА, 0,25%, крем для наружного применения. [General characteristics of the drug OFLOMIL DERMA, 0.25%, cream for external use] URL: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=636239e9fb44f16ca7fcc365&amp;codeId=P.MM.01 (accessed: 09.07.2025).</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2023;(30):149–166. doi: 10.1093/eurjpc/zwac204</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ламизил®. Актуальные возможности в лечении микозов кожи. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2012;1:48–54. [Lamisil®. Current opportunities in the treatment of skin mycoses. Effective Pharmacotherapy. Dermatovenereology and Dermatocosmetology. 2012;1:48–54. (In Russ.)]</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4):57. doi: 10.3390/jof3040057</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kyle AA, Dahl MV. Topical therapy for fungal infections. Am J Clin Dermatol. 2004;5(6):443–451. doi: 10.2165/00128071-200405060-00009</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002;16(1):19–33. doi: 10.1046/j.1468-3083.2002.00378.x</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991;42(4):659–672. doi: 10.2165/00003495-199142040-00008</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Spiekermann PH, Young MD. Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent. Arch Dermatol. 1976;112(3):350–352.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mullen GB, DeCory TR, Mitchell JT, Allen SD, Kinsolving CR, Georgiev VS. Studies on antifungal agents. 23. Novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)-2-alkylisoxazolidine derivatives. J Med Chem. 1988;31(10):2008–2014. doi: 10.1021/jm00118a027</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;2014(8):CD009992. doi: 10.1002/14651858.CD009992.pub2</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172(3):616–641. doi: 10.1111/bjd.13441</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: Undertaking network meta-analyses last updated October 2019 . Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. URL: https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-11 (accessed: 09.07.2025).</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane; 2024. URL: https://www.cochrane.org/authors/handbooks-and-manuals/handbook#how-to-cite (accessed: 09.07.2025).</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>NMA. PRISMA Statement. URL: https://www.prisma-statement.org/nma (accessed: 09.07.2025)</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Chapter 2: Determining the scope of the review and the questions it will address last updated August 2023. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. URL: https://www.cochrane.org/ru/authors/handbooks-and-manuals/handbook/current/chapter-02#gsc.tab=0&amp;gsc.q=PICO%20 (accessed 09.07.2025).</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Risk of bias tools — robvis (visualization tool) n.d. URL: https://www.riskofbias.info/welcome/robvis-visualization-tool (accessed 09.07.2025).</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79. doi: 10.1186/s13643-017-0473-z</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Balduzzi S, Rücker G, Nikolakopoulou A, Nikolakopoulou A, Papakonstantinou T. netmeta: An R Package for Network Meta-Analysis Using Frequentist Methods. Journal of Statistical Software. 2023;(106):1–40. doi: 10.18637/jss.v106.i02</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Selvan AT, Girisha G, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). International Research Journal of Pharmacy. 2013;4(6):224–228. doi: 10.7897/2230-8407.04651</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Chandana T, Shankaraiah P. Comparison of safety and efficacy of laliconazole and other antifungal agents. International Journal of Pharma Sciences and Research (IJPSR). 2014;5(1). URL: https://www.ijpsr.info/docs/IJPSR14-05-01-001.pdf</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Khan I. Topical Amorolfine, Luliconazole, Sertaconazole and Terbinafine Effectiveness in Tinea Corporis and Tinea Cruris: A Comparative Study. International Journal of Pharmaceutical and Clinical Research. 2019;5(2):11–115.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Smith EB, Wiss K, Hanifin JM, Jordon RE, Rapini RP, Lasser AE, et al. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad Dermatol. 1990;22(6Pt1):1116–1117. doi: 10.1016/s0190-9622(08)81020-1</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>el Darouti MA, al Raubaie S, Shandrashekhar CR, al Sawaf MH, Movahadi GA. Double-blind randomized comparative study of naftifine cream and clotrimazole cream in the treatment of dermatophytosis. Int J Dermatol. 1989;28(5):345–346. doi: 10.1111/j.1365-4362.1989.tb01362.x</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;1(1):CD012093. doi: 10.1002/14651858.CD012093.pub2</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Rad F, Nik-Khoo B, Yaghmaee R, Gharibi F. Terbinafin 1% Cream and Ketoconazole 2% Cream in the Treatment of Pityriasis Versicolor: A randomized comparative clinical trial. Pakistan Journal of Medical Sciences. 2014;30(6):1273–1276. doi: 10.12669/pjms.306.5509</mixed-citation></ref></ref-list></back></article>
